All of the following are agonist-antagonist opioids, except:

Bipolar disorder is a psychiatric condition characterized by alternating episodes of mania, hypomania, and depression. It reflects dysregulation of mood rather than a primary disturbance of thought processes or perception. The disorder involves fluctuations in energy, activity levels, and emotional state that significantly affect functioning. Classification as a mood disorder helps guide appropriate pharmacologic and psychotherapeutic management strategies.

Rationale:
A. Schizophrenic disorders primarily involve disturbances in thought processes, perception, and cognition, such as hallucinations, delusions, and disorganized thinking. While bipolar disorder can include psychotic features during severe mood episodes, its core pathology is not schizophrenia. Therefore, it does not fall under the schizophrenic category.

B. Depressive disorders are characterized by persistent low mood, anhedonia, and functional impairment without episodes of mania or hypomania. Although bipolar disorder includes depressive episodes, it is distinguished by the presence of manic or hypomanic phases. This dual-phase pattern separates it from unipolar depression.

C. Mood disorder classification is correct because bipolar disorder involves significant disturbances in emotional regulation, cycling between elevated and depressed mood states. The underlying pathology affects neurotransmitters such as serotonin, dopamine, and norepinephrine. This category includes both bipolar and depressive disorders, making it the most accurate.

D. Manic is not a diagnostic category but rather a symptom or phase within bipolar disorder. Mania represents elevated mood, increased energy, and impulsivity but does not define the overall disorder itself. Bipolar disorder encompasses both manic and depressive episodes, making “manic” an incomplete classification.

First-generation antipsychotics (FGAs) are dopamine D2 receptor antagonists used in the management of schizophrenia and other psychotic disorders. While effective for controlling positive symptoms, they are strongly associated with extrapyramidal side effects due to dopamine blockade in the nigrostriatal pathway. These adverse effects can range from acute movement disorders to delayed, often irreversible dyskinesias. Recognizing specific motor abnormalities is essential for early intervention and prevention of progression.

Rationale:
A. Akathisia is characterized by a subjective feeling of inner restlessness accompanied by observable motor agitation such as pacing or inability to sit still. It is distressing but does not involve abnormal involuntary facial or tongue movements.

B. Tardive dyskinesia is a late-onset extrapyramidal side effect of long-term dopamine blockade from First-generation antipsychotics. It is characterized by involuntary, repetitive, and often irreversible movements such as lip smacking, tongue protrusion, chewing motions, and “worm-like” tongue movements (lingual dyskinesia). It typically develops after prolonged treatment and may persist even after discontinuation of the drug.

C. Acute dystonia presents as sudden, sustained muscle contractions that can cause abnormal postures such as torticollis, oculogyric crisis, or jaw spasms. It usually occurs within hours to days of starting antipsychotic therapy. It is painful and dramatic but does not present as slow, writhing tongue movements or chewing difficulty.

D. Parkinsonism due to antipsychotics includes symptoms such as bradykinesia, rigidity, tremor, and a masked facial expression. It resembles Parkinson’s disease and results from dopamine blockade in the basal ganglia. However, it does not produce the choreoathetoid, repetitive oral-facial movements seen in tardive dyskinesia.